2010
DOI: 10.1111/j.1756-185x.2010.01581.x
|View full text |Cite
|
Sign up to set email alerts
|

Acute abdomen in SLE

Abstract: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune connective tissue disease with protean manifestations. Most often it presents with mucocutaneous, musculoskeletal or renal involvement. In comparison, gastrointestinal (GI) manifestations of SLE are far less common. The case presented here highlights the differential diagnosis of GI manifestations of SLE that range from non-life-threatening to serious life-threatening complications, including some of the complications of on-going drug treat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
14
0
1

Year Published

2011
2011
2021
2021

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 22 publications
(16 citation statements)
references
References 30 publications
1
14
0
1
Order By: Relevance
“…After IPO in SLE was first described in 1993,1 few cases have been reported thereafter 2-4. As in this case, IPO may appear as the initial presentation of SLE2 and be associated with interstitial cystitis 3-5.…”
mentioning
confidence: 54%
“…After IPO in SLE was first described in 1993,1 few cases have been reported thereafter 2-4. As in this case, IPO may appear as the initial presentation of SLE2 and be associated with interstitial cystitis 3-5.…”
mentioning
confidence: 54%
“…Leczenie polega na stosowaniu minimum przez 3 dni du偶ych dawek GKS, najcz臋艣ciej metyloprednizolonu w formie puls贸w do偶ylnych w dawce 1000-1500 mg/dob臋, z leczeniem immunosupresyjnym cyklofosfamidem. U pacjent贸w, kt贸rzy nie reaguj膮 na farmakoterapi臋, nale偶y przeprowadzi膰 natychmiastow膮 interwencj臋 chirurgiczn膮 [3,24].…”
Section: Leczenieunclassified
“…Differential diagnoses of life-threatening abdominal complications in SLE include lupus MV, intestinal pseudo-obstruction, and generalized megaviscera, acute pancreatitis (secondary to SLE or drug-related, i.e., AZA), protein-losing gastroenteropathy, and other less common entities (i.e., eosinophilic enteritis, pneumatosis cystoides intestinalis) 3 .…”
Section: To the Editormentioning
confidence: 99%